Loading organizations...
§ Private Profile · New Haven, CT, USA
Wellinks is a technology company.
Wellinks delivers virtual pulmonary rehabilitation and personalized chronic obstructive pulmonary disease management. Its integrated model combines one-on-one coaching with technology, including wearable sensors from its acquired Spire Health unit, for continuous monitoring and predictive insights. This approach provides comprehensive support, addressing critical gaps in traditional respiratory care.
Established in 2012, Wellinks recognized chronic respiratory care often lacked sufficient patient support. The company evolved to transform pulmonary care, developing a platform that offers tailored plans and direct access to medical professionals. This strategic pivot empowers individuals to actively manage their respiratory health and receive consistent, accessible care.
Wellinks serves patients with chronic respiratory conditions, collaborating with health plans and providers to deliver virtual care. The company's vision is to make breathing easier and more accessible by expanding access to essential pulmonary rehabilitation. It strives to enhance clinical outcomes, reduce healthcare costs, and enable patients to lead more fulfilling lives.
Wellinks has raised $42.4M across 4 funding rounds.
Wellinks has raised $42.4M in total across 4 funding rounds.
Wellinks is a New Haven, Connecticut-based technology company specializing in virtual-led cardiopulmonary care, particularly for chronic conditions like COPD and CHF.[1][3][4] It provides personalized respiratory care through connected devices, predictive analytics, virtual pulmonary rehabilitation, health coaching, and remote monitoring via a smartphone app, serving patients, providers, and payers to improve outcomes, reduce hospitalizations, and lower costs.[1][3][5] The company solves key challenges in chronic respiratory disease management—where less than 4% of eligible COPD patients access pulmonary rehabilitation—by enabling predictive interventions that detect complications early, often before symptoms appear.[1][5]
Wellinks demonstrates strong growth momentum, including its September 2024 acquisition of Spire Health to integrate novel patient monitoring technology and create a fully integrated Predictive Patient Care model.[1] Backed by investors like Morningside, HighCape Capital, Connecticut Innovations, and Benslie, it has expanded partnerships, such as with SoNE HEALTH for value-based COPD care in Connecticut and collaborations in New Jersey and Florida.[3][5]
Wellinks originated from early innovations in wearable health technology, with roots tracing to 2012 (per company history) or 2014 (per some profiles), founded by Ellen Su (designer and CEO), Levi DeLuke (engineer and scoliosis patient), and Sebastian Monzon (focused on healthcare optimization via sensors).[1][2] Initially developing "Cinch," a smart strap for scoliosis braces to monitor treatment compliance and connect to apps for doctors and parents, the company pivoted to pulmonary care, addressing gaps in chronic respiratory support.[2][4]
Pivotal moments include pioneering a portable connected nebulizer and evolving into virtual-first COPD management, empowering thousands of patients with care between clinic visits.[1][4] By 2024, under CEO Stacie Bratcher, it acquired Spire Health, adding machine learning-driven monitoring and board member Rich Wilmot from Gilde Healthcare, solidifying its leadership in predictive cardiopulmonary care.[1]
Wellinks stands out in digital health through:
Wellinks rides the wave of value-based care and remote patient monitoring (RPM) trends, amplified by post-pandemic telehealth adoption and AI-driven predictive health analytics.[1][5] Timing is ideal amid rising chronic cardiopulmonary burdens—COPD/CHF drive massive US healthcare costs—where traditional models fail due to low rehab access and reactive care.[1][3][5]
Market forces like payer demands for cost reduction, regulatory support for virtual care, and wearable sensor advancements favor Wellinks, positioning it to influence ecosystems by partnering with health plans and providers for scalable, evidence-based interventions.[5] It shapes digital health by demonstrating how integrated hardware-software platforms can prevent emergency care, inspiring similar models in other chronic disease areas.
Wellinks is poised to dominate predictive cardiopulmonary care, with Spire integration unlocking continuous data insights showcased at ATS 2025 and expanding value-based programs.[1][5] Upcoming trends like AI-enhanced wearables and broader RPM reimbursement will accelerate growth, potentially extending to more conditions beyond COPD/CHF.
Its influence may evolve through deeper payer integrations and tech partnerships, solidifying as an industry leader in preventing costly complications—transforming "live fully and breathe freely" from mission to standard.[4] This builds on its innovative roots, from smart braces to predictive platforms, delivering sustained impact in respiratory health.
Wellinks has raised $42.4M across 4 funding rounds. Most recently, it raised $25.0M Series C in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2021 | $25M Series C | Stephen Bruso | Connecticut Innovations, Digitalis Ventures, MPM Capital, Benslie International Fund, Highcape Capital, Stonehenge Capital | Announced |
| Sep 1, 2019 | $14M Series B | — | Connecticut Innovations, Digitalis Ventures, MPM Capital | Announced |
| Sep 1, 2017 | $3M Series U | — | Connecticut Innovations, Digitalis Ventures, MPM Capital | Announced |
| Apr 1, 2016 | $350K Series U | — | Connecticut Innovations, Digitalis Ventures, MPM Capital | Announced |
Wellinks has raised $42.4M in total across 4 funding rounds.
Wellinks's investors include Stephen Bruso, Connecticut Innovations, Digitalis Ventures, MPM Capital, Benslie International Fund, HighCape Capital, Stonehenge Capital.